Table of Content

1. Key Insights

2. Executive Summary of C-Met NSCLC

3. SWOT Analysis of C-Met NSCLC

4. C-Met NSCLC: Market Overview at a Glance
4.1. Total Market Share (%) Distribution of NSCLC in 2017: By Country
4.2. Total Market Share (%) Distribution of NSCLC in 2030: By Country

5. C-Met Non-small Cell Lung Cancer (NSCLC): Disease Background and Overview
5.1. Introduction
5.1.1. Cellular Classification of NSCLC
5.1.2. Signs and Symptoms of NSCLC
5.1.3. Risk Factors of Lung Cancer
5.1.4. Causes of NSCLC
5.1.5. Disease Biology: NSCLC

6. Diagnosis of NSCLC
6.1. Diagnostic Algorithm for NSCLC
6.2. Stages of NSCLC
6.3. Staging System

7. Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Total Incident cases of NSCLC patients in the 7MM
7.3.2. Total Incident cases of NSCLC patients by Histology in the 7MM
7.3.3. Total Diagnosed cases of NSCLC patients by Stages in the 7MM
7.4. The United States Epidemiology
7.4.1. Total Incident cases of NSCLC patients in the United States
7.4.2. Total Incident cases of NSCLC patients by Histology in the United States
7.4.3. Total Diagnosed cases of NSCLC patients by Stages in the United States
7.4.4. Total Incident cases of C-Met Mutated NSCLC in the United States

8. EU-5 Epidemiology
8.1. Germany
8.1.1. Total Incident cases of NSCLC patients in Germany
8.1.2. Total Incident cases of NSCLC patients by Histology in Germany
8.1.3. Total Diagnosed cases of NSCLC patients by Stages in Germany
8.1.4. Total Incident cases of C-Met Mutated NSCLC in Germany
8.2. France
8.2.1. Total Incident cases of NSCLC patients in France
8.2.2. Total Incident cases of NSCLC patients by Histology in France
8.2.3. Total Diagnosed cases of NSCLC patients by Stages in France
8.2.4. Total Incident cases of C-Met Mutated NSCLC in France
8.3. Italy
8.3.1. Total Incident cases of NSCLC patients in Italy
8.3.2. Total Incident cases of NSCLC patients by Histology in Italy
8.3.3. Total Diagnosed cases of NSCLC patients by Stages in Italy
8.3.4. Total Incident cases of C-Met Mutated NSCLC in Italy
8.4. Spain
8.4.1. Total Incident cases of NSCLC patients in Spain
8.4.2. Total Incident cases of NSCLC patients by Histology in Spain
8.4.3. Total Diagnosed cases of NSCLC patients by Stages in Spain
8.4.4. Total Incident cases of C-Met Mutated NSCLC in Spain
8.5. The United Kingdom
8.5.1. Total Incident cases of NSCLC patients in the United Kingdom
8.5.2. Total Incident cases of NSCLC patients by Histology in the United Kingdom
8.5.3. Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom
8.5.4. Total Incident cases of C-Met Mutated NSCLC in the United Kingdom

9. Japan Epidemiology
9.1. Japan
9.1.1. Total Incident cases of NSCLC patients in Japan
9.1.2. Total Incident cases of NSCLC patients by Histology in Japan
9.1.3. Total Diagnosed cases of NSCLC patients by Stages in Japan
9.1.4. Total Incident cases of C-Met Mutated NSCLC in Japan

10. Current Treatment Practices: NSCLC
10.1. Advanced/Metastatic NSCLC Treatment Algorithm
10.2. Chemotherapy
10.3. Targeted Therapy
10.4. Immunotherapy
10.5. Surgery
10.6. Radiation Therapy
10.7. Stage-wise Treatment Options of NSCLC

11. Guideline of NSCLC
11.1. The National Comprehensive Cancer Network (NCCN) Clinical Guidelines: 2020
11.2. The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up
11.3. The Spanish Society of Medical Oncology (SEOM) Clinical Guidelines: 2018
11.4. The Japanese Lung Cancer Society Guideline for NSCLC, Stage IV: 2018

12. Unmet Needs of C-Met NSCLC

13. Key Endpoints in C-Met NSCLC Clinical Trials

14. Emerging Therapies
14.1. Capmatinib (INC280): Novartis Pharmaceuticals
14.1.1. Product Description
14.1.2. Other Development Activities
14.1.3. Clinical Development
14.1.4. Safety and Efficacy
14.2. Tepmetko (tepotinib): Merck KGaA
14.2.1. Product Description
14.2.2. Other Development Activities
14.2.3. Clinical Development
14.2.4. Safety and Efficacy
14.3. Merestinib: Eli Lilly and Company
14.3.1. Product Description
14.3.2. Clinical Development
14.4. Telisotuzumab Vedotin: AbbVie
14.4.1. Product Description
14.4.2. Clinical Development
14.4.3. Safety and Efficacy
14.5. JNJ-61186372 (JNJ-6372): Janssen Research & Development
14.5.1. Product Description
14.5.2. Other Development Activity
14.5.3. Clinical Development
14.5.4. Safety and Efficacy
14.6. Canakinumab (ACZ885): Novartis Pharmaceuticals
14.6.1. Product Description
14.6.2. Clinical Development
14.7. Cabozantinib: Exelixis/Ipsen/Takeda
14.7.1. Product Description
14.7.2. Other Development Activities
14.7.3. Clinical Development
14.7.4. Safety and Efficacy
14.8. Sym015: Symphogen
14.8.1. Product Description
14.8.2. Clinical Development
14.8.3. Safety and Efficacy

15. C-Met Non-Small Cell Lung Cancer (NSCLC): Seven Major Market Analysis
15.1. Key Findings
15.2. Market Outlook: 7MM

16. c-MET Mutation?Market Size
16.1. Total Market Size of c-MET NSCLC in the 7MM
16.2. Market Size of c-MET NSCLC by Therapeutic Class in the 7MM
16.3. United States Market Size
16.3.1. Total Market size of c-MET NSCLC in the United States
16.4. EU-5 Market Size
16.4.1. Germany Market Size
16.4.2. France Market Size
16.4.3. Italy Market Size
16.4.4. Spain Market Size
16.4.5. United Kingdom Market Size
16.5. Japan Market Size
16.5.1. Total Market size of c-MET NSCLC in Japan

17. Market Drivers of C-Met NSCLC

18. Market Barriers of C-Met NSCLC

19. Appendix
19.1. Bibliography

20. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight



List of Figures


Figure 1 C-Met NSCLC SWOT Analysis
Figure 2 Major Types of NSCLC
Figure 3 Sign and Symptoms of NSCLC
Figure 4 Risks Factors of NSCLC
Figure 5 Alterations in Targetable Oncogenic Pathways in LUAD and LUSC
Figure 6 Schematic Illustration of the NSCLC Staging
Figure 7 Stage IA Lung Cancer
Figure 8 Stage IB Lung Cancer
Figure 9 Stage IIA Lung Cancer
Figure 10 Stage IIB Lung Cancer
Figure 11 Stage IIIA Lung Cancer
Figure 12 Stage IIIB Lung Cancer
Figure 13 Stage IVA Lung Cancer
Figure 14 Global Heat Map of Lung Cancer
Figure 15 Total Incident cases of NSCLC patients in the 7MM (2017–2030)
Figure 16 Total Incident cases of NSCLC patients by Histology in the 7MM (2017–2030)
Figure 17 Total Diagnosed cases of NSCLC patients by Stages in the 7MM (2017–2030)
Figure 18 Total Incident cases of NSCLC patients in the United States (2017–2030)
Figure 19 Total Incident cases of NSCLC patients by Histology in the United States (2017–2030)
Figure 20 Total Diagnosed cases of NSCLC patients by Stages in the United States (2017–2030)
Figure 21 Total Incident cases of C-Met Mutated NSCLC in the United States (2017–2030)
Figure 22 Total Incident cases of NSCLC patients in Germany (2017–2030)
Figure 23 Total Incident cases of NSCLC patients by Histology in Germany (2017–2030)
Figure 24 Total Diagnosed cases of NSCLC patients by Stages in Germany (2017–2030)
Figure 25 Total Incident cases of C-Met Mutated NSCLC in Germany (2017–2030)
Figure 26 Total Incident cases of NSCLC patients in France (2017–2030)
Figure 27 Total Incident cases of NSCLC patients by Histology in France (2017–2030)
Figure 28 Total Diagnosed cases of NSCLC patients by Stages in France (2017–2030)
Figure 29 Total Incident cases of C-Met Mutated NSCLC in France (2017–2030)
Figure 30 Total Incident cases of NSCLC patients in Italy (2017–2030)
Figure 31 Total Incident cases of NSCLC patients by Histology in Italy (2017–2030)
Figure 32 Total Diagnosed cases of NSCLC patients by Stages in Italy (2017–2030)
Figure 33 Total Incident cases of C-Met Mutated NSCLC in Italy (2017–2030)
Figure 34 Total Incident cases of NSCLC patients in Spain (2017–2030)
Figure 35 Total Incident cases of NSCLC patients by Histology in Spain (2017–2030)
Figure 36 Total Diagnosed cases of NSCLC patients by Stages in Spain (2017–2030)
Figure 37 Total Incident cases of C-Met Mutated NSCLC in Spain (2017–2030)
Figure 38 Total Incident cases of NSCLC patients in the United Kingdom (2017–2030)
Figure 39 Total Incident cases of NSCLC patients by Histology in the United Kingdom (2017–2030)
Figure 40 Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom (2017–2030)
Figure 41 Total Incident cases of C-Met Mutated NSCLC in the United Kingdom (2017–2030)
Figure 42 Total Incident cases of NSCLC patients in Japan (2017–2030)
Figure 43 Total Incident cases of NSCLC patients by Histology in Japan (2017–2030)
Figure 44 Total Diagnosed cases of NSCLC patients by Stages in Japan (2017–2030)
Figure 45 Total Incident cases of C-Met Mutated NSCLC in Japan (2017–2030)
Figure 46 Advanced/Metastatic NSCLC Treatment Algorithm
Figure 47 Unmet Needs
Figure 48 Market Size of c-MET NSCLC in the 7MM Countries, in USD Million (2017–2030)
Figure 49 Market Size of c-MET NSCLC by Line of therapies in the 7MM, in USD Million (2017–2030)
Figure 50 Market Size of c-MET NSCLC by therapies by in the 7MM, in USD Million (2017–2030)
Figure 51 Market Size of c-MET NSCLC in the United States by Therapies, in USD Millions (2017–2030)
Figure 52 Market Size of c-MET NSCLC in France, in USD Millions (2017–2030)
Figure 53 Market Size of c-MET NSCLC by therapies in Italy, in USD Millions (2017–2030)
Figure 54 Market Size of c-MET NSCLC by therapies in Spain, in USD Millions (2017–2030)
Figure 55 Market Size of c-MET NSCLC by Therapies in the United Kingdom, in USD Millions (2017–2030)
Figure 56 Market Size of c-MET NSCLC by therapies in Japan, in USD Millions (2017–2030)
Figure 57 Market Drivers
Figure 58 Market Barriers

 

List of Tables


Table 1 Summary of C-Met Non-small-cell Lung Cancer (NSCLC) Market, Epidemiology, and Key Events (2017–2030)
Table 2 TNM Staging of NSCLC
Table 3 Total Incident cases of NSCLC patients in the 7MM (2017–2030)
Table 4 Total Incident cases of NSCLC patients by Histology in the 7MM (2017–2030)
Table 5 Total Diagnosed cases of NSCLC patients by Stages in the 7MM (2017–2030)
Table 6 Total Incident cases of NSCLC patients in the United States (2017–2030)
Table 7 Total Incident cases of NSCLC patients by Histology in the United States (2017–2030)
Table 8 Total Diagnosed cases of NSCLC patients by Stages in the United States (2017–2030)
Table 9 Total Incident cases of C-Met Mutated NSCLC in the United States (2017–2030)
Table 10 Total Incident cases of NSCLC patients in Germany (2017–2030)
Table 11 Total Incident cases of NSCLC patients by Histology in Germany (2017–2030)
Table 12 Total Diagnosed cases of NSCLC patients by Stages in Germany (2017–2030)
Table 13 Total Incident cases of C-Met Mutated NSCLC in Germany (2017–2030)
Table 14 Total Incident cases of NSCLC patients in France (2017–2030)
Table 15 Total Incident cases of NSCLC patients by Histology in France (2017–2030)
Table 16 Total Diagnosed cases of NSCLC patients by Stages in France (2017–2030)
Table 17 Total Incident cases of C-Met Mutated NSCLC in France (2017–2030)
Table 18 Total Incident cases of NSCLC patients in Italy (2017–2030)
Table 19 Total Incident cases of NSCLC patients by Histology in Italy (2017–2030)
Table 20 Total Diagnosed cases of NSCLC patients by Stages in Italy (2017–2030)
Table 21 Total Incident cases of C-Met Mutated NSCLC in Italy (2017–2030)
Table 22 Total Incident cases of NSCLC patients in Spain (2017–2030)
Table 23 Total Incident cases of NSCLC patients by Histology in Spain (2017–2030)
Table 24 Total Diagnosed cases of NSCLC patients by Stages in Spain (2017–2030)
Table 25 Total Incident cases of C-Met Mutated NSCLC in Spain (2017–2030)
Table 26 Total Incident cases of NSCLC patients in the United Kingdom (2017–2030)
Table 27 Total Incident cases of NSCLC patients by Histology in the United Kingdom (2017–2030)
Table 28 Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom (2017–2030)
Table 29 Total Incident cases of C-Met Mutated NSCLC in the United Kingdom (2017–2030)
Table 30 Total Incident cases of NSCLC patients in Japan (2017–2030)
Table 31 Total Incident cases of NSCLC patients by Histology in Japan (2017–2030)
Table 32 Total Diagnosed cases of NSCLC patients by Stages in Japan (2017–2030)
Table 33 Total Incident cases of C-Met Mutated NSCLC in Japan (2017–2030)
Table 34 Standard Treatment Options of NSCLC (Stage-wise)
Table 35 Summary of Recommendations (SEOM Clinical Guideline)
Table 36 Strength of Evidence
Table 37 Strength of Evidence
Table 38 Capmatinib (INC280), Clinical Trial Description, 2020
Table 39 Tepotinib, Clinical Trial Description, 2020
Table 40 Merestinib, Clinical Trial Description, 2020
Table 41 Telisotuzumab Vedotin (ABBV-399), Clinical Trial Description, 2020
Table 42 JNJ-61186372 (JNJ-6372), Clinical Trial Description, 2020
Table 43 Lazertinib (YH25448), Clinical Trial Description, 2020
Table 44 Canakinumab (ACZ885), Clinical Trial Description, 2020
Table 45 7MM Market Size of c-MET NSCLC, in USD Million (2017–2030)
Table 46 7MM Market Size of c-MET NSCLC by Line of Therapy, in USD Million (2017–2030)
Table 47 7MM Market Size of c-MET NSCLC by therapies, in USD Million (2017–2030)
Table 48 United States Market Size of c-MET NSCLC by Line of Therapy, in USD Million (2017–2030)
Table 49 United States Market Size of c-MET NSCLC by Therapies, in USD Million (2017–2030)
Table 50 Germany Market Size of c-MET NSCLC by Line of Therapy, in USD Million (2017–2030)
Table 51 Germany Market Size of c-MET NSCLC by Therapies, in USD Million (2017–2030)
Table 52 France Market Size ofc-MET NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 53 France Market Size of c-MET NSCLC by Therapies, in USD Million (2017–2030)
Table 54 Italy Market Size of c-MET NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 55 Italy Market Size of c-MET NSCLC by Therapies, in USD Million (2017–2030)
Table 56 Spain Market Size of c-MET NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 57 Spain Market Size of c-MET NSCLC by Therapies, in USD Million (2017–2030)
Table 58 United Kingdom Market Size of c-MET NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 59 United Kingdom Market Size of c-MET NSCLC by Therapies, in USD Million (2017–2030)
Table 60 Japan Market Size of c-MET NSCLC by Line of Therapy, in USD Million (2017–2030)
Table 61 Japan Market Size ofc-MET NSCLC by Therapies, in USD Million (2017–2030)